Identification of Serum CMTM2 as a Potential Biomarker for HBV-Related Disorders

Table 1

Clinical characteristics of subjects in this study.

Parameter	HC	CHB	HBLC	HCC
Number of subjects; (proportion of HBV DNA assessment, %)	52	69 (84%)	77 (39%)	53 (15%)
Age (range)	21-91	21-78	30-75	35-75
Year (mean)	48.1	44.1	54.4	56
Sex (male: female)	40 : 12	53 : 16	51 : 26	48 : 5
HBsAg positive	No	Yes	Yes	Yes
CMTM2 (pg/ml)	1379.8 ± 356.5	843.2 ± 325.0	866.6 ± 420.0	831.9 ± 343.0
ALT (U/l)	17 ± 6.6	235.1 ± 324.2	42.9 ± 49.4	56.0 ± 58.9
AST (U/l)	19.75 ± 4.83	173.7 ± 206.7	60.9 ± 69.8	76.9 ± 91.1
HBV DNA (copies/ml)	N/A^†	8480136 ± 46763772	5508195 ± 20426271	16381 ± 30431

For CMTM2 values, ALT, AST, HBV DNA titres, data are presented as mean ± SD. ^†N/A not available. HC: healthy control; CHB: chronic hepatitis B; HBLC: hepatitis B associated liver cirrhosis; HCC: hepatocellular carcinoma; HBsAg: hepatitis B surface antigen; CMTM2: CKLF-like MARVEL transmembrane domain containing 2; ALT: alanine transaminase; AST: aspartate aminotransferase; HBV DNA: hepatitis B virus deoxyribonucleic acid.